Investor Information

4Q and FY2013 Results and FY2014 Guidance release
Aug 2, 2013 at 6:30 AM ET
4Q and FY2013 Results and FY2014 Guidance call
Aug 2, 2013 at 8:00 AM ET
IMGN (Common Stock)
Exchange NASDAQ GS
Price 15.96
Change (%) Stock is Down 0.42 (2.564%)
Volume 531,900
Data as of 06/19/13 4:00 PM
Minimum 20 minute delay Refresh quote

Corporate Profile

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s TAP technology uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's highly potent cancer cell-killing agents specifically to tumor cells. Ten TAP compounds are now in the clinic, of which three are wholly owned by the Company. The most advanced compound using ImmunoGen's TAP technology, Kadcyla™, has been approved for marketing in the US and Switzerland, and is undergoing regulatory review in the European Union and Japan. Kadcyla is being commercialized in the US by Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.

Shareholder Inquiries

Inquiries related to the Company may be directed to the Investor Relations department at our headquarters. Communications related to stock and transfer requirements, including lost stock certificates and change of name or address, should be directed to the Transfer Agent.

Corporate Headquarters

ImmunoGen, Inc.
830 Winter Street
Waltham, MA 02451-1477
Phone: (781) 895-0600
Email: info@immunogen.com

Transfer Agent and Registrar

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
Phone: (877) 830-4936
Fax: (215) 553-5402
E-mail: shareholder@broadridge.com

Corporate Counsel

Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.
Boston, MA

Independent Accountants

Ernst & Young LLP
Boston, MA

Receive E-mail AlertsE-mail Alert Icon

Sign up to receive e-mail alerts whenever ImmunoGen, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Quotes delayed at least 20 minutes. Market data provided by eSignal.